11Sep 2024
Cyclophosphamide vs. Mycophenolate Mofetil in Childhood Nephrotic Syndrome

Cyclophosphamide vs. Mycophenolate Mofetil in Childhood Nephrotic Syndrome

A study comparing oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) for treating steroid-sensitive nephrotic syndrome in children found similar efficacy for both drugs in terms of response rates. In the CYC group, 50% of patients were responders, while 54% of MMF patients met the response criteria (p = 0.614). The time to first relapse was similar for both treatments, with CYC and MMF showing 7 months (IQR 5.25–11) and 7 months (IQR 3.5–12) respectively (p = 0.092). However, the relapse rate was significantly lower in the MMF group (1.295 relapses per patient-year) compared to the CYC group (1.77 relapses per patient-year) (p = 0.009). Younger age at treatment initiation was associated with better response to MMF (p = 0.039). Overall, MMF demonstrated comparable efficacy to CYC with fewer relapses and favorable treatment outcomes.

  • #nephrology

Like

Save

Share